|
Market Closed -
Nasdaq
16:00:00 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 4.220 USD | +2.68% |
|
+14.05% | +78.81% |
| 10-14 | Rezolute Says Phase 3 upLIFT Study Fully Enrolled, Topline Data Due Mid-December | MT |
| 10-14 | Rezolute, Inc. Completes Enrollment In Phase 3 upLIFT Study Of Ersodetug In Tumor Hyperinsulinism | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| REZOLUTE, INC. | Bio Therapeutic Drugs | +2.68% | +14.05% | +78.81% | -55.34% | -35.08% | 431M |  |  | |
- Stock Market
- Stocks
- RZLT Stock
- Charts Rezolute, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
